Gold Track: Accelerating the growth of massively scalable healthcare companies

What if there were someone in your life sciences network you could turn to for answers to all your questions and concerns? Someone with a proven track record of creating highly successful healthcare businesses, to help you realise the true potential of your own?

Gold Track pairs promising companies with top-flight life science advisors who immerse themselves in your ideating, strategising, and operational execution to set you on a path to success.

With its ambition to massively scale these businesses, Gold Track is built on personal relationships between mentors and mentees. Through individualised guidance, we support companies in unlocking ambitious business and investment opportunities within short timeframes as you conquer unmet medical needs.

Powered by our operator Advise Connect Inspire (ACI), Gold Track’s accelerator model has been validated across multiple European programmes. Gold Track has led to companies raising over €500M, securing 24 partnerships and achieving three exits.

Are you the next Gold Track company?

Apply

Our vision

Gold Track aspires to build optimism in the European life science ecosystem by creating success stories. These stories demonstrate to entrepreneurs and investors that European life science companies can be competitive globally.

What you get

How Gold Track works

Apply

1 of 6

Submit an application with your company, team and product/service information. You can apply at any time throughout the year.

Get selected

2 of 6

To compete for a place in the programme, a selection of companies will need to convince at least one Expert Council member to champion your company at a Gold Track workshop.

Reflect with experts

3 of 6

We assemble a carefully curated group of experts to assess your company’s current status, identify any important gaps, and set business priorities.

Set your goals and execute

4 of 6

Together, we’ll define 2-4 business objectives and commit to achieving results with the support of our mentors and experts.

Assess your progress

5 of 6

You’ll report back to the Expert Council at the next Gold Track workshop to discuss your achievements, adjust goals, and assess whether you’ll continue on in the programme.

Graduate

6 of 6

After successfully completing the three phases of the programme, you will become an EIT Health Alumni—and continue to receive support and benefits from our network.

Gold Track workshops

Gold Track is a competitive programme based around three four-month phases. Each phase begins and ends with a highly interactive workshop.

At each workshop, current and new Gold Track companies compete for their place in the next phase. You’ll have 1:1 and group sessions with Expert Council members and the opportunity to present to additional hand-picked investors and industry partners.

Our workshops are held across Europe three times per year. The next workshops are:

13-14 October 2022

Austria

9-10 February 2023

Portugal

14-15 June 2023

Location – TBD

Meet the Expert Council

In Gold Track, you’ll learn from and work with the Expert Council members — successful entrepreneurs, investors, and top industry executives. You’ll also work with other domain experts in our extensive global network specifically recruited to match your individual business needs.

  • Constantin-Schwaab

    Constantin Schwaab

    Founder and CEO, Kinoheld
    CEO, Wirelane

    Constantin Schwaab is a serial entrepreneur who has pursued an active role as a life sciences investor in companies such as Quanta, NVision, and Merlion. Constantin is the CEO of Wirelane, a technology company focused on infrastructure solutions in the space of electromobility. He is a founder and CEO of Kinoheld, a market leading platform for movie tickets which was acquired by a global leader in live entertainment, the German CTS Eventim AG. Prior to this, Constantin was the founder and managing partner of Plain Energy, a Europe-wide PV-plant developer with approx. €50m assets under management. He is an experienced project manager with 10 years of expertise in all facets of the PV industry including power plant developments in 5 countries, and a strong track record along the value chain including site development, construction, financing and operation. Constantin started his career as the founder of one of the largest European e-commerce sites at its time; with a successful exit in 2007, when it was sold to NYSE Euronext listed as Loyaltouch. Constantin studied political sciences at the Ludwig-Maximilians-Universität in Munich, the Uni Mail in Geneva and the UB in Barcelona. He speaks 4 languages, successfully competed in the endurance sports competition Iron Man Triathlon and has three kids.

    LinkedIn Read Bio
  • Christoph Lengauer

    Co-Founder and CSO, Curie.bio

    Christoph is an enthusiastic company builder who is dedicated to translating science into application; he has contributed to the discovery and development of eight FDA-approved cancer medicines.  Christoph is currently the co-founder and CSO at Curie.bio. Before founding Curie.bio, Christoph was a partner at Third Rock Ventures where he had been instrumental in founding and launching several companies including Blueprint Medicines (BPMC), Relay Therapeutics (RLAY), Thrive Earlier Detection, Celsius Therapeutics, and MOMA Therapeutics. He currently serves as a consultant in R&D strategy at Thrive Earlier Detection.  Several years ago, Christoph founded Advice Connect Inspire (ACI) to provide both strategic consulting and hands-on operational support to startups and young European companies so they can more easily succeed globally.


    Prior to joining Third Rock, he was CSO and chief drug hunter at Blueprint Medicines, global head of oncology drug discovery at Sanofi, and senior unit head of oncology discovery at Novartis. Prior to Novartis, Christoph was an associate professor at the Johns Hopkins University School of Medicine where he was involved in the identification of several cancer driver genes including PIK3CA and BRAF. As part of his research, Christoph discovered that all cancers are genetically unstable, which explains the molecular heterogeneity of cancer and why cancers develop resistance to drugs. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature, and Science. Christoph studied human genetics in Salzburg, Austria and got his PhD in biology from the University of Heidelberg in Germany. He received his MBA with a focus on medical services management from the Johns Hopkins Carey Business School.   


    Christoph has received numerous awards, including the Novartis Oncology President’s Award for Top Innovator. He has been elected to membership in the Johns Hopkins Society of Scholars. Christoph is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller and HBO movie The Immortal Life of Henrietta Lacks. He coached the Johns Hopkins Women’s soccer team for several years and was director of coaching at the Baltimore Bays Premier Soccer Club.  

    LinkedIn Read Bio
  • Erich F. Greiner

    CEO and Founder, Cedrus Therapeutics Inc.

    Erich founded Cedrus Therapeutics Inc. in May 2008 to develop novel therapeutic concepts and medicines. He is also an independent board member of several biotech companies including Cellerys AG (Cofounder, Chairman), PharmaBiome AG (Chairman), Tolremo Therapeutics AG and Topas Therapeutics GmbH (Chairman).

    Prior to that, he held various senior positions at Evotec, including Chief Innovation Officer and Member of the Management Team. He was responsible for science, corporate strategy and corporate development from 2002 through 2008 and initiated several business collaborations and public-private partnerships including the European Screening Port and the NEU2 BioPharma Consortium.

    Prior to joining Evotec, Erich was a Research Associate at the German Research Cancer Center in Heidelberg, from where he spun off Pointer Pharmaceuticals AG (later PheneX Pharmaceuticals). Erich was trained in mathematics and medicine at the Friedrich-Alexander University of Erlangen-Nürnberg and the Duke University Medical Center in Durham, NC, USA.

    He serves as a strategic advisor and reviewer for several governmental, public and private institutions in the US and in Europe, including the German Federal Ministry of Education and Research and the Federal Ministry for Health.

    Read Bio
  • Dawn Bell

    Global Development Head, Strategic Partnerships, Novartis

    Dawn Bell, Pharm.D. is a biopharma executive, former start-up CEO and Board Director with experience at large and mid-sized public pharmaceutical companies, as well as early stage and start-up privately held biotech companies. Her areas of expertise span strategic planning, portfolio prioritisation, clinical development, business development, market access and commercialisation. Dr. Bell is currently Global Development Head of Strategic Partnerships at Novartis where she is responsible for portfolio strategy for internal and external white space opportunities. She is also a board member and member of the audit and finance committee for The Metabolomics Innovation Center in Edmonton, Alberta, a nationally-funded research facility. She is a passionate mentor for seed stage life-sciences start-ups in the Creative Destruction Lab (Toronto, Canada) as well as EIT Health’s Gold Track Programme.

    LinkedIn Read Bio
  • Graziano Seghezzi

    Managing Partner, Sofinnova Partners

    Graziano Seghezzi is Managing Partner at Sofinnova Partners which he joined in 2006. He seed funded and was on the Board of GlycoVaxyn which was sold to GlaxoSmithKline in 2015 and Omthera Pharmaceuticals which went public on Nasdaq in 2013, then was sold to AstraZeneca later that year. Graziano also seed funded and is on the Board of Mission Therapeutics, Crescendo Biologics, Hookipa Biotech, Corvidia, Hotspot Therapeutics, Polyneuron and Erydel. He promoted and is on the Board of BiovelocITA, Italy’s first biotech accelerator. Graziano started his career in venture capital in 2001 at Sofinnova Partners and then joined Index Venture in 2003.

    LinkedIn Read Bio
  • Ida-Beerhalter

    Ida Beerhalter

    Co-head, IOME

    Ida Beerhalter is Co-head of IOME, a private investment office of women principals from the Persian Gulf with its head office in Riyadh, Kingdom of Saudi Arabia. She currently serves as Member of the Board of Auma Obama Foundation Sauti Kuu (Germany and Kenya), and is Head of Family Office Investments Division at Green Sands Equity (USA). She serves as Strategic Advisor to Impact Investment Partners LLP (United Kingdom), is Vice Chairman of the board of Trustees of First Light Trust (United Kingdom), and is a Member of the Advisory Board of Professors Without Boarders (United Kingdom) and the Arab African Economic Development Initiative (Nigeria & Dubai). She is also a Member of the Board of Jim Button Foundation (Germany), Ambassador to TBLI Group (Netherlands), and Spokesperson of the advisory board of the Charité Entrepreneurship Summitt (Germany).

    LinkedIn Read Bio
  • Jens Eckstein

    Managing Partner, Apollo Health Ventures

    Jens Eckstein has more than 15 years of venture capital experience in biopharma and 10 years of operational experience in drug discovery and development. Jens is a Kauffman Fellow and a mentor for life science entrepreneurs and start-up teams in the area of innovative life science and healthcare IT companies.

    LinkedIn Read Bio
  • Lorenz Mayr

    CEO, Vector BioPharma

    Dr. Mayr is the CEO of Vector BioPharma. Prior to Vector BioPharma, Dr. Mayr has been the Chief Technology Officer for GE Healthcare Life Sciences and was responsible for all R&D investments, research programmes, business growth strategy, technology innovation, and R&D talent development across all business areas (BioProcess, Imaging Diagnostics/Contrast Media, Research Tools and Applied Markets, Cell & Gene Therapy, New Opportunities). Previously, he has been working as Vice President & Global Head, Reagents & Assay Development with responsibility for generation of all biological reagents and assay development activities across all therapeutic research areas at AstraZeneca.

    LinkedIn Read Bio
  • Montse Vendrell

    Partner, Alta Life Sciences

    Montserrat Vendrell is partner at Alta Life Sciences since 2016. She sits in the board of Peptomyc, Accure Therapeutics (Chair), Ona Therapeutics and Inbrain Neuroelectronics (observer). Prior to Alta Life Sciences, Vendrell was founder and CEO of Biocat (Catalonia biocluster), and the Barcelona Science Park and its bioincubator. Vendrell also chairs the Executive Committee of the Pasqual Maragall Foundation (Alzheimer’s research) and the Board of Trustees of UPF (Pompeu Fabra University).

    LinkedIn Read Bio
  • Regina Hodits

    Managing Partner, Wellington Partners Life Sciences

    Regina Hodits is a Managing Partner at Wellington Partners Life Sciences (WPLS) and represents the WPLS funds on the Boards of AYOXXA, Endostim, GTX Medical, Polares Medical, Themis, and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis/ Boston Scientific), and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European venture capital industry, focusing on early-stage and growth deals in Life Sciences.

    LinkedIn Read Bio
  • Valentin Piëch

    Partner, BioMed Partners

    Dr. Valentin Piëch joined BioMed in 2015 with a background in venture capital, science, and technology. Dr. Piëch founded impact2partners AG, a private venture capital firm with a focus on companies developing treatments and diagnostics for rare diseases. Prior to impact2partners, he was Investment Analyst and then Principal at Nextech Invest, a venture capital firm focusing on oncology. In addition, he is a private investor in a number of startup and growth companies.

    Read Bio
  • Vincent Hennemand

    COO, Intergalactic Therapeutics

    Vincent Hennemand is the COO at Intergalactic Therapeutics. He was previously Senior Vice President of Strategy, Corporate & Business Development at Akili Interactive Labs. Prior to that he was a Principal in Sanofi’s corporate R&D venture group (“Sunrise”) where he was responsible for developing and managing new investment opportunities including Myokardia, Voyager Therapeutics, WarpDrive Bio, and Portal Instruments.

    LinkedIn Read Bio
  • Vishal Gulati

    Venture Partner, Molten Ventures

    Dr. Vishal Gulati serves as a venture partner at Molten Ventures. Specialising in Digital Health, Dr. Gulati previously served at DFJ Esprit, Europe’s leading Silicon Valley style Venture Capital firm with over $1b under management. Since 2012, Vishal has been a leading promoter of investments into the emerging Digital Health sector and Chairman of Digital Health Forum, which supports the best-in-class Digital Health companies to grow into global enterprises. Vishal serves on several boards including Horizon Discovery Group PLC (Cambridge, UK), a gene editing company; Fluidics Analytics (Cambridge, UK), a next gen protein discovery engine; Frameshift Healthcare Information Flow Platform (London, UK) and EcoEos (San Francisco, USA), a consumer genomics business. His previous investments include Napo Pharmaceuticals, Glenmark, Renovo and Phagenesis.

    LinkedIn Read Bio
  • Werner Lanthaler

    CEO, Evotec

    Dr. Werner Lanthaler was appointed Chief Executive Officer of Evotec AG in 2009. In his previous position, Dr. Lanthaler served as Chief Financial Officer of Intercell AG in Vienna, Austria, a global biopharmaceutical leader dedicated to the development of vaccines. In this role, he was also responsible for Business Development and Marketing & Sales.

    LinkedIn Read Bio
  • Derek Young - In Memoriam

    Founder & CEO, i360medical Ltd.

    Derek Young was an entrepreneur and innovator in the healthcare sector. He was a named inventor of over 32+ patents with commercial success globally. Mr. Young successfully co-founded a number of European medical device start-up companies including Medtech, Advanced Surgical Concepts, and Haptica before joining the Royal College of Surgeons (RCSI) in Dublin. While there, he established a Healthcare Innovation Hub to develop ideas received from clinicians and inventors in Europe and internationally. Mr. Young spearheaded and completed at least 12 Medical Device Exits with key International Healthcare MNC over the last 12 years.

    LinkedIn Read Bio
X

Who should apply

Gold Track is open to companies that:

  • have the potential to address unmet medical needs, backed by strong science and technology
  • operate in healthcare/ life sciences, such as therapeutics, diagnostics, platform technologies, medtech, or digital health
  • have a committed leadership team and a financial runway of at least nine months
  • are privately-owned with less than 50 employees and based in Europe, the UK, or Israel
  • previously EIC supported ventures receive unique benefits – download the call document to learn more

Join other Gold Track companies

Ready to apply?

We accept applications on a rolling basis. Gold Track is free to enter and to participate. We do not take equity in your company or charge any consulting fees. If we are successful in enabling you to achieve significant financial events, we ask to partake in your financial success by charging a nominal success fee on your upside.

Will you be the next Gold Track company?

Apply now

Any questions?

Do you have any questions or expectations for the Gold Track programme? We welcome interested companies to schedule a one-hour pitch session in which you’ll be able to meet the Gold Track team and tell us more about your company.

Have your pitch deck ready and feel free to invite 1-2 core team members to this pitch session.

Schedule session

Are you an investor or corporate partner?

Join us in shaping tomorrow’s healthcare businesses and leaders.

Get involved in Gold Track and get early access to Europe’s most promising companies with the potential to massively scale. Gold Track operates synergistically with venture groups to identify hidden gems across Europe, develop and de-risk promising companies for investment, and create value through expanded access to business and investment opportunities. You’ll also get a chance to network with other high-profile investors and industry experts during our exclusive events.

Get in touch

Meet the Gold Track team

Gold Track is an EIT Health initiative, designed and operated in collaboration with Advise Connect Inspire (ACI). We bring a strong track record of building successful life science companies. Contact us to learn more

  • Christina Hertel

    Programme Manager

  • Steve Laken

    CEO ACI

  • Jessie Liu

    Company support and identification

  • Raquel Riera

    Company support and identification

  • Sara Cipolat

    Consultant

  • Tanja Krainz

    ACI Managing Director

X